Beckman Coulter Diagnostics on Tuesday announced it has acquired StoCastic, an artificial intelligence (AI) company that provides evidence-based decision support for hospital emergency departments, for an undisclosed amount.
StoCastic has developed TriageGo, a triage decision-support tool that will be the cornerstone of Beckman Coulter's AI-enabled clinical decision-support portfolio, Beckman said.
The tool seamlessly integrates electronic health record systems and routine emergency department workflows, the firm said.
Although emergency department triage differentiates patients' criticality, between 60% and 70% of all patients in the U.S. are triaged to an ambiguous Emergency Severity Index Level 3, meaning the projected course of care is uncertain, Beckman noted.
TriageGo has been shown to reduce decision-making times in the emergency department, including decreasing door-to-clinical decision time by 20 to 30 minutes, door-to-intensive care unit times by 40 to 80 minutes, and door-to-emergency department departure for those having emergency surgery by 30 to 60 minutes, Beckman said.
"With the StoCastic acquisition, we combine Beckman Coulter Diagnostics biomarkers with TriageGo's evidence-based [clinical decision support] to generate advanced decision support insights,” Kelly Sager, vice president and general manager for clinical decision-support solutions at Beckman Coulter Diagnostics, said in a statement. “This will enable clinicians to make informed decisions sooner and further improve patient outcomes."
TriageGo was developed by researchers at Johns Hopkins Medicine. The transaction was completed on October 3, and all associates of StoCastic have joined Beckman Coulter's Clinical Decision Support business.